FUNDAMENTAL AND CLINICAL EVALUATIONS OF DL-8280 IN OBSTETRICAL AND GYNECOLOGICAL FIELD

DL-8280, a new oxazine derivative synthetic antibacterial agent, was evaluated on antibacterial susceptibility, pharmocokinetics and clinical efficacy against obstetrical and gynecological infections, and the following results were obtained. The antibacterial activity of DL-8280 was very high agains...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 32; no. Supplement1; pp. 908 - 924
Main Authors CHO, NANKUN, KOH, YOSHIMITSU, HARA, YUTAKA, FUKUDA, TAKEO, NOGUCHI, YUSEI, KONDO, HIDEYA, KATO, HIROSHI, FUKUNAGA, KANGO, KUNII, KATSUAKI
Format Journal Article
LanguageJapanese
Published Japanese Society of Chemotherapy 1984
Online AccessGet full text

Cover

Loading…
More Information
Summary:DL-8280, a new oxazine derivative synthetic antibacterial agent, was evaluated on antibacterial susceptibility, pharmocokinetics and clinical efficacy against obstetrical and gynecological infections, and the following results were obtained. The antibacterial activity of DL-8280 was very high against clinical isolates, with the MIC80 value of <0.05μg/ml against E. coil, 0.10μg/ml against Proteus spp., 0.20μg/ml against S. aureus and K. pneumoniae, 0.39μg/ml against P. aeruginosa and Citrobacter, 0.78μg/ml against S. epidermidis and S. faecalis and 3.12μg/ml against S. marcescens. Concentrations in serum and intrapelvic genital organs such as uterine and adnexal tissues were determined following oral administration. Tissue penetration of DL-8280 was found to be good, with the tissue levels of 1.30-5.37μg/g after oral administration of 200mg and 3.99-7.80μg/g after administration of 300mg. Those tissue levels of DL-8280 exceeded the MIC80 values against most causative organisms. DL-8280 was given to 62 cases of obstetrical and gynecological infections with a daily dose of 150-600mg and 98% of clinical efficacy and 80% of bacterial response were obtained. No side effect was observed.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.32.Supplement1_908